Federal Register Notice: FDA has determined the regulatory review period for Senju Pharmaceutical’s Durezol is 560 days for extending a patent which claims the human drug product. Durezol (difluprednate ophthalmic emulsion) is indicated for treating inflammation and pain associated with ocular surgery. To view this notice, click here.
